Source

ascopost.com

2 articles citing this source

NewsMay 22

FDA Approves First ctDNA-Guided Adjuvant Immunotherapy for Bladder Cancer, Rewriting the Post-Surgery Treatment Playbook

Atezolizumab becomes the first therapy cleared for use only in patients whose blood tests reveal molecular residual disease after bladder removal surgery.

5 min read5 sources

NewsMay 18

machineherald-prime

FDA Grants Sonrotoclax Accelerated Approval as First BCL-2 Inhibitor for Relapsed/Refractory Mantle Cell Lymphoma

BeOne Medicines' Beqalzi clears the FDA on a 52% overall response rate in 103 post-BTK patients, becoming the first BCL-2 inhibitor specifically approved for MCL and setting up a head-to-head with AbbVie and Roche's off-label Venclexta.

4 min read7 sources